| Depenbrock PJ. Long-term standard-dose warfarin to prevent thrombosis. Am Fam Physician 1941;72:36 | A |
| Stiegler H. [Venous thrombosis--diagnosis and treatment.] MMW Fortschr Med 1969;153:65–7 | A |
| Prandoni P, Mannucci PM. Deep-vein thrombosis of the lower limbs: diagnosis and management. Baillieres Clinical Haematology 1994;7:693–712 | A |
| Chesterman CN. After a first episode of venous thromboembolism. BMJ 1995;311:700–1 | A |
| Hirsh J. The optimal duration of anticoagulant therapy for venous thrombosis. N Engl J Med 1995;332:1710–11 | A |
| Hirsh J, Kearon C, Ginsberg J. Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia. Arch Intern Med 1997;157:2174–7 | A |
| Solymoss S. Optimising the duration of anticoagulation therapy for venous thrombosis. CMAJ 1999;160:1317–18 | A |
| van der Heijden JF, Kraaijenhagen RA, Buller HR. The risk of recurrent venous thrombosis. N Engl J Med 2000;342:214–15 | A |
| Schulman S. Duration of anticoagulants in acute or recurrent venous thromboembolism. Curr Opin Pulm Med 2000;6:321–5 | A |
| Schulman S. Optimal duration of anticoagulation therapy after venous thromboembolism. Arch Hellenic Med 2000;17:A71–4 | A |
| Diet F. [Optimum duration of anticoagulation for deep-vein thrombosis – How long?] Herz Kreislauf 2000;32:16–18 | A |
| Dickey TL. Can thrombophilia testing help to prevent recurrent VTE? Part 2. JAAPA 2002;15:23–4 | A |
| Bounameaux H. [Venous thromboembolism recurrence: is there a place for D-dimer?] Rev Med Interne 2002;23:810–12 | A |
| Levesque H. [Risk of haemorrhage with oral anticoagulants for deep-vein thrombosis.] J Mal Vasc 2002;27:129–36 | A |
| D’Angelo A, Piovella F. Optimal duration of oral anticoagulant therapy after a first episode of venous thromboembolism: where to go? Haematologica 2002;87:1009–13 | A |
| Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002;87:7–12 | A |
| Douketis JD, Crowther MA. Identifying patients at increased risk for recurrent venous thromboembolism: clinical, biochemical, and radiologic risk factors. Cardiovasc Rev Rep 2002;23:280–5 | A |
| Chodri TA, Groth ML. Optimal duration of anticoagulation therapy for idiopathic deep-vein thrombosis. Clin Pulm Med 2002;9:131–2 | A |
| Brotman DJ. Identifying patients at risk of recurrent venous thromboembolism. JAMA 2003;290:3192 | A |
| van Dongen CJ, Vink R, Hutten BA, Buller HR, Prins MH. Recurrent thromboembolism after treatment with vitamin K antagonists. Arch Intern Med 2003;163:2793–822 | A |
| Kyrle PA, Eichinger S. The risk of recurrent venous thromboembolism: the Austrian study on recurrent venous thromboembolism. Wien Klin Wochenschr 2003;115:471–4 | A |
| Hyers TM. Duration of anticoagulation in venous thromboembolism. Arch Intern Med 2003;163:1265–6 | A |
| Ridker PM, Goldhaber SZ, Glynn RJ. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. N Engl J Med 2003;49:2164–7 | A |
| Seneviratne C, Kupfer Y, Tessler S. Low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:398–400 | A |
| Preventing idiopathic DVT recurrence. Med Today 2003;4:9 | A |
| Dargaud Y. [Predictive value of D dimer in recurrent venous thromboembolism.] Hematologie 2003;9:281–2 | A |
| Prandoni P, Pagnan A. The optimal long-term treatment of venous thromboembolism: current status and future perspectives. Cardiovasc Rev Rep 2003;24:468–72 | A |
| Goldhaber SZ. Prevention of recurrent idiopathic venous thromboembolism. Circulation 2004;110:IV20–4 | A |
| Palareti G, Cosmi B. Predicting the risk of recurrence of venous thromboembolism. Curr Opin Hematol 2004;11:192–7 | A |
| Abdel-Razeq HN, Radwi GR. Duration of anticoagulation after first episode of unprovoked venous thromboembolism. Saudi Med J 2004;25:1776–7 | A |
| Agnelli G. Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: no. J Thromb Haemost 2004;2:1038–40 | A |
| Elliott CG, Rubin LJ. Mars or venus – is sex a risk factor for recurrent venous thromboembolism? N Engl J Med 2004;350:2614–16 | A |
| Boger C, Schroll S, Holmer S. Ximelagatran for secondary prevention of venous thromboembolism. N Engl J Med 2004;350:618–19 | A |
| Becattini C, Agnelli G. Duration of anticoagulant treatment after venous thromboembolism. Pathophysiol Haemost Thromb 2004;33:354–7 | A |
| Agnelli G, Becattini C, Prandoni P, Nieto JA, Monreal M, Kahn SR, et al. Recurrent venous thromboembolism in men and women. N Engl J Med 2004;351:2015–18 | A |
| Cosmi B, Palareti G. D-dimer, oral anticoagulation, and venous thromboembolism recurrence. Semin Vasc Med 2005;5:365–70 | A |
| Rychlik PG, Henry KS, Bussey HI. Duration of treatment of deep-vein thrombosis: time for a new approach? Pharmacotherapy 2005;25:1112–15 | A |
| Couturaud F, Lacut K, Gut-Gobert C, Leroyer C, Mottier D. [Long term antivitamin K therapy: what degree of anticoagulation, what efficiency and risk?] Sang Thrombose Vaisseaux 2005;17:23–31 | A |
| Kamphuisen PW. Can anticoagulant treatment be tailored with biomarkers in patients with venous thromboembolism? J Thromb Haemost 2006;4:1206–7 | A |
| Cosmi B. Value of D-dimer testing to decide duration of anticoagulation after deep-vein thrombosis: yes. J Thromb Haemost 2006;4:2527–9 | A |
| Baglin T. Value of D-dimer testing to decide duration of anticoagulation after deep-vein thrombosis: not yet. J Thromb Haemost 2006;4:2530–2 | A |
| Pengo V, Prandoni P. Sex and anticoagulation in patients with idiopathic venous thromboembolism. Lancet 2006;368:342–3 | A |
| Betancourt MT, Rodger MA. Risk stratification for recurrent venous thromboembolism in unprovoked venous thromboembolism patients. Acta Chir Belg 2007;107:636–40 | A |
| Baglin T. Unprovoked deep-vein thrombosis should be treated with long-term anticoagulation – no. J Thromb Haemost 2007;5:2336–9 | A |
| Kearon C. Indefinite anticoagulation after a first episode of unprovoked venous thromboembolism: yes. J Thromb Haemost 2007;5:2330–5 | A |
| Pernod G, Sevestre MA, Labarere J. D-dimer and duration of anticoagulation. N Engl J Med 2007;356:421 | A |
| Garcia D. Duration of anticoagulant therapy for patients with venous thromboembolism. Thromb Res 2008;123:S62–4 | A |
| Righini M, Perrier A. [D-dimers measurement to predict the risk of thromboembolic recurrence.] Revue de Medecine Interne 2008;29:476–81 | A |
| Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. J Thromb Thrombolysis 2008;25:37–44 | A |
| Kearon C. Stopping anticoagulant therapy after an unprovoked venous thromboembolism. CMAJ 2008;179:401–2 | A |
| Prandoni P. Recurrence of venous thromboembolism and its prevention. Phlebolymphology 2008;15:3–11 | A |
| Cortese F. Is lifelong anticoagulation worth the risk in patients with unprovoked DVT? Ann Intern Med 2009;151:827 | A |
| Eichinger S, Kyrle PA. Duration of anticoagulation after initial idiopathic venous thrombosis – the swinging pendulum: risk assessment to predict recurrence. J Thromb Haemost 2009;7:291–5 | A |
| Siragusa S, Caramazza D, Malato A. How should we determine length of anticoagulation after proximal deep-vein thrombosis of the lower limbs? Br J Haematol 2009;144:832–7 | A |
| Madhusudhana S, Moore A, Moormeier JA. Current issues in the diagnosis and management of deep-vein thrombosis. Mo Med 2009;106:43–8 | A |
| Pabinger I, Ay C. Biomarkers and venous thromboembolism. Arterioscler Thromb Vasc Biol 2009;29:332–6. | A |
| Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol 2009;29:298–310 | A |
| Raju NC, Hirsh J, Eikelboom JW. Duration of anticoagulant therapy for venous thromboembolism. Med J Aust 2009;190:659–60 | A |
| Goldhaber SZ. Is lifelong anticoagulation worth the risk in patients with unprovoked DVT? Ann Intern Med 2009;151:827 | A |
| Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet 2010;376:2032–9 | A |
| Kearon C, Iorio A, Palareti G, Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardised reporting. J Thromb Haemost 2010;8:2313–15 | A |
| East AT, Wakefield TW. What is the optimal duration of treatment for DVT? An update on evidence-based medicine of treatment for DVT. Semin Vasc Surg 2010;23:182–91 | A |
| Rodger M, Carrier M, Gandara E, Le Gal, G. Unprovoked venous thromboembolism: short term or indefinite anticoagulation? Balancing long-term risk and benefit. Blood Rev 2010;24:171–8 | A |
| Reitter S, Laczkovics C, Waldhoer T, Mayerhofer M, Vutuc C, Pabinger I. Long-term survival after venous thromboembolism: a retrospective selected cohort study among young women. Haematologica 2010;95:1425–8 | A |
| Malato A, Saccullo G, Iorio A, Ageno W, Siragusa S. Residual vein thrombosis and D-dimer for optimising duration of anticoagulation in idiopathic deep-vein thrombosis. Curr Pharm Des 2010;16:3483–6 | A |
| Spurzem JR, Geraci SA. Outpatient management of patients following pulmonary embolism. Am J Med 2010;123:987–90 | A |
| Cosmi B, Palareti G. Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism. Thromb Res 2010;125:S62–5 | A |
| Holmes G. Optimum duration of anticoagulation for idiopathic venous thromboembolism. J R Coll Physicians Edinb 2010;40:380 | A |
| Hunt JM, Bull TM. Clinical review of pulmonary embolism: diagnosis, prognosis, and treatment. Med Clin North Am 2011;95:1203–22 | A |
| Van EJ, Eerenberg ES, Kamphuisen PW, Buller HR. How to prevent, treat, and overcome current clinical challenges of VTE. J Thromb Haemost 2011;9:265–74 | A |
| Rodger MA, Ramsay T, Le Gal G, Carrier M. Assessment of recurrence risk after unprovoked venous thromboembolism. Ann Intern Med 2011;154:644 | A |
| Fujita T. Risk assessment for recurrent venous thrombosis. Lancet 2011;377:1072–3 | A |
| Donadini MP, Ageno W. Which patients with unprovoked VTE should receive extended anticoagulation? The minority. J Thromb Thrombolysis 2011;31:301–5 | A |
| Lindhoff-Last E. [Risk assessment of recurrence of venous thromboembolism.] Hamostaseologie 2011;31:7–12 | A |
| De Stefano V, Za T, Ciminello A, Betti S, Rossi E. Testing for inherited thrombophilia and predictive value for venous thromboembolism. 10th International Winter Meeting on Coagulation: Basic, Laboratory and Clinical Aspects of Venous and Arterial Thromboembolic Diseases, Bormio, Italy, 10–16 October 2011 | A |
| Baglin T. Using the laboratory to predict recurrent venous thrombosis. Int J Lab Hematol 2011;33:333–42 | A |
| Oo TH. Optimal duration of anticoagulation in idiopathic venous thromboembolism should be determined by multiple variables. J R Coll Physicians Edinb 2011;41:91–2 | A |
| Risk of recurrence after venous thromboembolism. Drug Ther Bull 2011;49:51 | A |
| Cosmi B, Legnani C, Iorio A, Pengo V, Ghirarduzzi A, Testa S, et al. [Referat zu: Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep-vein thrombosis in the prolong study.] Vasomed 2011;23:97–8 | A |
| Iorio A, Douketis J. Assessment of recurrence risk after unprovoked venous thromboembolism. Ann Intern Med 2011;154:644 | A |
| Spencer FA, Ginberg JS. Recurrence after unprovoked venous thromboembolism. BMJ 2011;342:508 | A |
| Goldhaber SZ, Piazza G. Optimal duration of anticoagulation after venous thromboembolism. Circulation 2011;123:664–7 | A |
| Emadi A, Streiff M. Diagnosis and management of venous thromboembolism: an update a decade into the new millennium. Arch Iran Med 2011;14:341–51 | A |
| Sinescu C, Hostiuc M, Bartos D. Idiopathic venous thromboembolism and thrombophilia. J Med Life 2011;4:57–62 | A |
| Kroger A, Ulrich-Somaini S. [Pulmonary embolism.] Praxis 2011;100:453–62 | A |
| Kyrle PA. Treatment of venous thrombosis – a view of the future. 55th Annual Meeting of the Gesellschaft fur Thrombose und Hamostaseforschung, GTH 2011, Wiesbaden, Germany, 16–19 February 2011 | A |
| Prandoni P, Piovella C, Spiezia L, Dalla VF, Pesavento R. The optimal duration of anticoagulation in patients with venous thromboembolism: how long is long enough? Panminerva Medica 2012;54:39–44 | A |
| Geersing GJ, Oudega R, Hoes AW, Moons KG. Managing pulmonary embolism using prognostic models: future concepts for primary care. CMAJ 2012;184:305–10 | A |
| Eichinger S, Kyrle PA. Duration of anticoagulation after venous thrombosis. Vasa 2012;41:11–17 | A |
| Baglin T, Bauer K, Douketis J, Buller H, Srivastava A, Johnson G. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep-vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost 2012;10:698–702 | A |
| Kyrle PA, Eichinger S, Kyrle PA, Eichinger S. Clinical scores to predict recurrence risk of venous thromboembolism. Thromb Haemost 2012;108:1061–4 | A |
| Hamann H, Reuchlin G. [Secondary prevention after leg and pelvic vein thrombosis with low-molecular-weight heparin.] Vasa Suppl 1992;35:107–8 | B |
| Sudlow MF, Campbell IA, Angel JH, Bentley DP, Fennerty AG, Prescott RJ, et al. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992;340:873–6 | B |
| Monreal M, Lafoz E, Ruiz J, Callejas JM, Arias A. Recurrent pulmonary embolism in patients treated because of acute venous thromboembolism: a prospective study. Eur J Vasc Surg 1994;8:584–9 | B |
| Sarasin FP, Bounameaux H. Duration of oral anticoagulant therapy after proximal deep-vein thrombosis: a decision analysis. Thromb Haemost 1994;71:286–91 | B |
| Sarasin FP, Bounameaux H. Duration of oral anticoagulant therapy after proximal deep-vein thrombosis: a decision analysis. Medecine et Hygiene 1994;52:2309–13 | B |
| Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995;92:2800–2 | B |
| Meissner MH, Caps MT, Bergelin RO, Manzo RA, Strandness DE Jr. Propagation, rethrombosis and new thrombus formation after acute deep venous thrombosis. J Vasc Surg 1995;22:558–67 | B |
| Schulman S, Rhedin A-S, Lindmarker P, Carlsson A, Larfars G, Nicol P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661–5 | B |
| Schulman S, Wiman B. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group. Thromb Haemost 1996;75:607–11 | B |
| White RH, Zhou H, Romano PS. Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism. Arch Intern Med 1998;158:1005–10 | B |
| Sparano N, English R. Extended anticoagulation for a first episode of idiopathic venous thromboembolism. J Fam Pract 1999;48:579–80 | B |
| Schulman S. The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolisms. Duration of Anticoagulation Study Group. Wiener Medizinische Wochenschrift 1999;149:66–9 | B |
| Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 1999;81:684–9 | B |
| Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden – cost-effectiveness analysis. Thromb Haemost 2000;84:752–7 | B |
| Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457–62 | B |
| Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton LJ III. Predictors of recurrence after deep-vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761–8 | B |
| Hansson PO, Sorbo J, Eriksson H. The recurrence rate of venous thromboembolism after a first or second episode of deep venous thrombosis was high. Evid Based Med 2000;5:188 | B |
| Lindmarker P, Schulman S. The risk of ipsilateral versus contralateral recurrent deep-vein thrombosis in the leg. J Intern Med 2000;247:601–6 | B |
| Farquhar D. Duration of anticoagulant therapy for deep-vein thrombosis. CMAJ 2001;165:636 | B |
| Eichinger S, Weltermann A, Mannhalter C, Minar E, Bialonczyk C, Hirschl M, et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med 2002;162:2357–60 | B |
| Fattorini A, Crippa L, Vigano’ DS, Pattarini E, D’Angelo A. Risk of deep-vein thrombosis recurrence: high negative predictive value of D-dimer performed during oral anticoagulation. Thromb Haemost 2002;88:162–3 | B |
| Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002;87:7–12 | B |
| Schonauer V, Kyrle PA, Weltermann A, Minar E, Bialonczyk C, Hirschl M, et al. Superficial thrombophlebitis and risk for recurrent venous thromboembolism. J Vasc Surg 2003;37:834–8 | B |
| Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003;139:893–900 | B |
| Palareti G, Legnani C, Cosmi B, Valdre L, Lunghi B, Bernardi F, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003;108:313–18 | B |
| van Dongen CJ, Vink R, Hutten BA, Buller HR, Prins MH. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med 2003;163:1285–93 | B |
| Ombandza-Moussa E, Samama MM, Horellou MH, Elalamy I, Conard J. Potential use of D-dimer measurement in patients treated with oral anticoagulant for a venous thromboembolic episode. Int Angiol 2003;22:364–9 | B |
| Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362:523–6 | B |
| Biron-Andreani C. Evaluation of risk of recurrent venous thromboembolism: role of D-dimers. Angeiologie 2003;55:37–9 | B |
| Marcucci R, Liotta AA, Cellai AP, Rogolino A, Gori AM, Giusti B, et al. Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med 2003;115:601–5 | B |
| Spiezia L, Bernardi E, Tormene D, Simioni P, Girolami A, Prandoni P. Recurrent thromboembolism in fertile women with venous thrombosis: incidence and risk factors. Thromb Haemost 2003;90:964–6 | B |
| Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004;350:2558–63 | B |
| Eichinger S, Weltermann A, Minar E, Stain M, Schonauer V, Schneider B, et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 2004;164:92–6 | B |
| Willey VJ, Bullano MF, Hauch O, Reynolds M, Wygant G, Hoffman L, et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther 2004;26:1149–59 | B |
| Cristina L, Benilde C, Michela C, Mirella F, Giuliana G, Gualtiero P. High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol 2004;124:504–10 | B |
| Baglin T, Luddington R, Brown K, Baglin C. High risk of recurrent venous thromboembolism in men. J Thromb Haemost 2004;2:2152–5 | B |
| Monaco J, Newton W. Elevated D-dimer level predicts recurrent VTE. J Fam Pract 2004;53:20–3 | B |
| Cosmi B, Legnani C, Cini M, Guazzaloca G, Palareti G. D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep-vein thrombosis. Thromb Haemost 2005;94:969–74 | B |
| Garcia-Fuster MJ, Forner MJ, Fernandez C, Gil J, Vaya A, Maldonado L. Long-term prospective study of recurrent venous thromboembolism in patients younger than 50 years. Pathophysiol Haemost Thromb 2005;34:6–12 | B |
| Hoke M, Kyrle PA, Minar E, Bialonzcyk C, Hirschl M, Schneider B, et al. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb Haemost 2005;94:787–90 | B |
| Eriksson H, Lundstrom T, Wahlander K, Clason SB, Schulman S, THRIVE III Investigators. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. Thromb Haemost 2005;94:522–7 | B |
| Palareti G, Legnani C, Cosmi B, Guazzaloca G, Cini M, Mattarozzi S. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. J Thromb Haemost 2005;3:955–61 | B |
| Schulman S, Lundstrom T, Walander K, Billing CS, Eriksson H. Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study. Thromb Haemost 2005;94:820–4 | B |
| Ost D, Tepper J, Mihara H, Lander O, Heinzer R, Fein A. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA 2005;294:706–15 | B |
| Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005;293:2352–61 | B |
| Young L, Ockelford P, Milne D, Rolfe-Vyson V, Mckelvie S, Harper P. Post-treatment residual thrombus increases the risk of recurrent deep-vein thrombosis and mortality. J Thromb Haemost 2006;4:1919–24 | B |
| Legnani C, Mattarozzi S, Cini M, Cosmi B, Favaretto E, Palareti G. Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. Br J Haematol 2006;134:227–32 | B |
| Shrivastava S, Ridker PM, Glynn RJ, Goldhaber SZ, Moll S, Bounameaux H, et al. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost 2006;4:1208–14 | B |
| Hron G, Eichinger S, Weltermann A, Quehenberger P, Halbmayer WM, Kyrle PA. Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. J Thromb Haemost 2006;4:752–6 | B |
| Schulman S, Lindmarker P, Holmstrom M, Larfars G, Carlsson A, Nicol P, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006;4:734–42 | B |
| van Hylckama Vlieg A, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 2007;138:769–74 | B |
| Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep-vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007;92:199–205 | B |
| Poli D, Antonucci E, Ciuti G, Abbate R, Prisco D. Anticoagulation quality and the risk of recurrence of venous thromboembolism. Thromb Haemost 2007;98:1148–50 | B |
| Prandoni P, Hutten BA, van Dongen CJ, Pesavento R, Prins MH. Quality of oral anticoagulant treatment and risk of subsequent recurrent thromboembolism in patients with deep-vein thrombosis. J Thromb Haemost 2007;5:1555 | B |
| Kyrle PA, Hron G, Eichinger S, Wagner O. Circulating P-selectin and the risk of recurrent venous thromboembolism. Thromb Haemost 2007;97:880–3 | B |
| Kamphuisen PW. 6 or 3 months of anticoagulant therapy did not differ for treatment failure in patients with DVT, PE, or both. Evid Based Med 2007;12:143 | B |
| Eichinger S, Hron G, Kollars M, Kyrle PA. Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. 2008;54:2042–8 | B |
| Coppens M, Reijnders JH, Middeldorp S, Doggen CJ, Rosendaal FR. Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J Thromb Haemost 2008;6:1474–7 | B |
| Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 2008;6:1720–5 | B |
| Cosmi B, Legnani C, Cini M, Favaretto E, Palareti G. D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep-vein thrombosis. Thromb Res 2008;122:610–17 | B |
| Eichinger S, Hron G, Bialonczyk C, Hirschl M, Minar E, Wagner O, et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008;168:1678–83 | B |
| Siragusa S, Malato A, Anastasio R, Cigna V, Milio G, Amato C, et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep-vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood 2008;112:511–15 | B |
| Poli D, Antonucci E, Ciuti G, Abbate R, Prisco D. Combination of D-dimer, F1 + 2 and residual vein obstruction as predictors of VTE recurrence in patients with first VTE episode after OAT withdrawal. J Thromb Haemost 2008;6:708–10 | B |
| Baglin T, Palmer CR, Luddington R, Baglin C. Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. J Thromb Haemost 2008;6:577–82 | B |
| Linnemann B, Zgouras D, Schindewolf M, Schwonberg J, Jarosch-Preusche M, Lindhoff-Last E. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry. Blood Coagul Fibrinolysis 2008;19:159–65 | B |
| Lechner D, Wiener C, Weltermann A, Eischer L, Eichinger S, Kyrle PA. Comparison between idiopathic deep-vein thrombosis of the upper and lower extremity regarding risk factors and recurrence. J Thromb Haemost 2008;6:1269–74 | B |
| Legnani C, Palareti G, Cosmi B, Cini M, Tosetto A, Tripodi A, et al. Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study. Haematologica 2008;93:900–7 | B |
| Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Alatri A, et al. Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. J Thromb Thrombolysis 2009;28:381–8 | B |
| Haspel J, Bauer K, Goehler A, Roberts DH. Long-term anticoagulant therapy for idiopathic pulmonary embolism in the elderly: a decision analysis. Chest 2009;135:1243–51 | B |
| Prandoni P, Prins MH, Lensing AW, Ghirarduzzi A, Ageno W, Imberti D, et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomised trial. Ann Intern Med 2009;150:577–85 | B |
| Taliani MR, Becattini C, Agnelli G, Prandoni P, Moia M, Bazzan M, et al. Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities. Thromb Haemost 2009;101:596–8 | B |
| Kim TM, Kim JS, Han SW, Hong YS, Kim I, Ha J, et al. Clinical predictors of recurrent venous thromboembolism: a single institute experience in Korea. Thromb Res 2009;123:436–43 | B |
| Prandoni P, Lensing AWA, Prins MH. Ultrasonography to guide duration of anticoagulation in DVT. Ann Intern Med 2009;151:826–7 | B |
| Lijfering WM, Veeger NJGM, Middeldorp S, Hamulyak K, Prins MH, Buller HR, et al. A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood 2009;114:2031–6 | B |
| Block JP. Ultrasonography may help guide decisions to discontinue anticoagulation therapy for deep venous thrombosis. J Clin Outcomes Manag 2009;16:304–5 | B |
| Tripodi A, Legnani C, Palareti G, Chantarangkul V, Mannucci PM. More on: high thrombin generation and the risk of recurrent venous thromboembolism. J Thromb Haemost 2009;7:906–7 | B |
| Garcia DA. Review: D-dimer concentrations predict risk of recurrent VTE after anticoagulant therapy is stopped. Evid Based Med 2009;14:59 | B |
| Lee C-H, Yang Y-H, Lin L-J, Cheng C-L. The relationship between the length of oral anticoagulation and recurrence of venous thromboembolism in Taiwan – a nationwide population-base study. 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Providence, RI, 16–19 September 2009 | B |
| Marcucci M, Iorio A, Douketis J, Baglin T, Cushman M, Eichinger S, et al. D-dimer to predict thrombosis recurrence: comparison of aggregate data and individual patient data meta-analyses. 22nd Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, 11–16 July 2009 | B |
| Reitter SE, Laczkovics C, Waldhoer T, Vutuc C, Pabinger-Fasching I. Long-term survival after venous thromboembolism: a cohort study among young women. 22nd Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, 11–16 July 2009 | B |
| Douketis J, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Does the clinical presentation of venous thromboembolism predict the risk for and type of thrombosis recurrence? 22nd Congress of the International Society of Thrombosis and Haemostasis Boston, MA, 11–16 July 2009 | B |
| Grifoni E, Ciuti G, Poli D, Antonucci E, Marcucci R, Arcangeli C, et al. Hyperhomocysteinemia and risk of venous thromboembolism recurrence after a first episode of pulmonary embolism. 22nd Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, 11–16 July 2009 | B |
| Cosmi B, Legnani C, Pengo V, Tosetto A, Ghirarduzzi A, Alatri A, et al. D-dimer and sex as risk factors for recurrence after a first episode of venous thromboembolism in the extended follow-up of the prolong study. 22nd Congress of the International Society of Thrombosis and Haemostasis Boston, MA, 11–16 July 2009 | B |
| Emmerich J, Zhu T, Carcaillon L, Martinez I, Olie V, Remones V, et al. Risk factor for the prediction of recurrent venous thromboembolism. 22nd Congress of the International Society of Thrombosis and Haemostasis Boston, MA, 11–16 July 2009 | B |
| Iorio A, Douketis J, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. D-dimer to predict thrombosis recurrence after unprovoked venous thromboembolism: effect of patient-and D-dimer-related factors on recurrence prediction. 22nd Congress of the International Society of Thrombosis and Haemostasis Boston, MA, 11–16 July 2009 | B |
| Ten Cate-Hoek AJ, Dielis AJWH, Spronk HMH, Van OR, Hamulyak K, Prins MH, et al. Increasing levels of thrombin generation precede recurrent DVT. 22nd Congress of the International Society of Thrombosis and Haemostasis Boston, MA, 11–16 July 2009 | B |
| Douketis J, Lorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Does patient sex and prior hormonal therapy predict risk for thrombosis recurrence after a first venous thromboembolism? 22nd Congress of the International Society of Thrombosis and Haemostasis Boston, MA, 11–16 July 2009 | B |
| Hron G, Eischer L, Eichinger S, Kyrle PA. Risk of recurrence among heterozygous carriers of Factor II (FII) G20210A and a first unprovoked venous thromboembolism (VTE). 22nd Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, 11–16 July 2009 | B |
| Conard J, Ombandza-Moussa E, Samama MM, Turpie AG, Horellou MH, Elalamy I. D-dimer testing, thrombophilia screening and recurrences in patients with venous thromboembolism: a 6-year follow-up. European Society of Cardiology, ESC Congress 2009 Barcelona, Spain, 29 August–2 September 2009 | B |
| Zotz RB, Gerhardt A. Risk stratification of recurrent venous thromboembolism. 51st Annual Meeting of the American Society of Haematology, New Orleans, LA, 5–8 December 2009 | B |
| Makelburg ABU, Middeldorp S, Hamulyak K, Prins M, Buller HR, Lijfering WM. Thrombophilia and cardiovascular risk factors on the absolute risk of first and recurrent venous thrombosis. Results from a retrospective family cohort study involving 2097 relatives. 51st Annual Meeting of the American Society of Haematology, New Orleans, LA, 5–8 December 2009 | B |
| Baglin T, Douketis J, Tosetto A, Marcucci M, Cushman M, Kyrle P, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost 2010;8:2436–42 | B |
| Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, et al. Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the prolong study extension. J Thromb Haemost 2010;8:1933–42 | B |
| Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med 2010;153:523–31 | B |
| Mello TB, Orsi FL, Montalvao SA, Ozelo MC, de Paula EV, Nichinno-Bizzachi JM. Long-term prospective study of recurrent venous thromboembolism in a Hispanic population. Blood Coagul Fibrinolysis 2010;21:660–5 | B |
| Deitelzweig SB, Lin J, Kreilick C, Hussein M, Battleman D. Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. Adv Ther 2010;27:623–33 | B |
| Tripodi A, Legnani C, Lemma L, Cosmi B, Palareti G, Chantarangkul V, et al. Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. J Thromb Thrombolysis 2010;30:215–19 | B |
| Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, et al. Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study. Thromb Haemost 2010;103:1152–60 | B |
| Lijfering WM, Middeldorp S, Veeger NJ, Hamulyak K, Prins MH, Buller HR, et al. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation 2010;121:1706–12 | B |
| Cosmi B, Legnani C, Iorio A, Pengo V, Ghirarduzzi A, Testa S, et al. Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep-vein thrombosis in the prolong study. Eur J Vasc Endovasc Surg 2010;39:356–65 | B |
| Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, et al. Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood 2010;115:481–8 | B |
| Eischer L, Tscholl V, Heinze G, Traby L, Kyrle PA, Eichinger S. Haematocrit and the risk of recurrent venous thrombosis: a prospective cohort study. 52nd Annual Meeting of the American Society of Haematology, Orlando, FL , 4–7 January 2010 | B |
| Kondal D, Taglalakis V, Moride Y, Boivin J-F, Kahn S. A Large, Population based study of sex differences in the risk of recurrent venous thromboembolism. Conference: 52nd Annual Meeting of the American Society of Haematology, Orlando, FL, 4–7 January 2010 | B |
| Sonnevi K, Tchaikovski SN, Bremme K, Holmstrom M, Professor JR, Larfars G. High thrombin generation measured in the presence of activated protein C is associated with an increased risk of recurrence among women 18–64 years after a first event of VTE. 52nd Annual Meeting of the American Society of Haematology, 2010 Orlando, FL, 4–7 January 2010 | B |
| [Blood coagulation self management facilitates anticoagulant therapy. Reduces risk of complications and mortality.] MMW Fortschritte der Medizin 2010;152:44–5 | B |
| Jimenez D, Aujesky D, Diaz G, Monreal M, Otero R, Marti D, et al. Prognostic significance of deep-vein thrombosis in patients presenting with acute symptomatic pulmonary embolism. M J Respir Crit Care Med 2010;181:983–91 | B |
| Legnani C, Cosmi B, Cini M, Palareti G. Different cut-off values of quantitative D-dimer (DD) assays to establish duration of oral anticoagulation treatment (OAT) after venous thromboembolism (VTE). 20th International Society on Fibrinolysis and Proteolysis, ISFP Congress Amsterdam, Netherlands, 24–28 August 2010 | B |
| Cosmi B, Legnani C, Iorio A, Pengo V, Ghirarduzzi A, Testa S, et al. Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep-vein thrombosis in the PROLONG study. 11th Meeting of the European Venous Forum, EVF 2010 Antwerp, Belgium, 24–16 June 2010 | B |
| Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. D-dimer to determine risk for disease recurrence after unprovoked venous thromboembolism: addressing unanswered questions with a large individual patient meta-analysis. 21st International Congress on Thrombosis – The Start of a New Era – Antithrombotic Agents, Milan, Italy, 6–9 July 2010 | B |
| Marcucci M, Douketis JD, Tosetto A, Tudur-Smith C, Baglin T, Cushman M, et al. D-dimer to predict recurrence after a first episode of unprovoked venous thromboembolism: comparison of individual patient and aggregate data meta-analysis. 21st International Congress on Thrombosis – The Start of a New Era – Antithrombotic Agents, Milan, Italy, 6–9 July 2010 | B |
| Baglin T, Douketis J, Tosetto A, Marcucci M, Cushman M, Eichinger S, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient level meta-analysis of 2,554 unselected patients after a first thrombosis. 21st International Congress on Thrombosis – The Start of a New Era – Antithrombotic Agents Milan, Italy, 6–9 July 2010 | B |
| Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Are men at higher risk for disease recurrence than women. 21st International Congress on Thrombosis – The Start of a New Era – Antithrombotic Agents, Milan, Italy, 6–9 July 2010 | B |
| Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, et al. Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. 21st International Congress on Thrombosis – The Start of a New Era – Antithrombotic Agents, Milan, Italy, 6–9 July 2010 | B |
| Siragusa S, Malato A, Saccullo G, Lo CL, Paolo GF, Iorio A, et al. Idiopathic vein thrombosis: identification of populations at different risk of relapse following oral anticoagulant treatment. The results of the ‘Extended-DACUS Study’. 21st International Congress on Thrombosis – The Start of a New Era – Antithrombotic Agents, Milan, Italy, 6–9 July 2010 | B |
| Chantarangkul V, Tripodi A, Legnani C, Lemma L, Cosmi B, Palareti G, et al. Abnormal Agkistrodon contortrix contortrix venom-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent VTE. 21st International Congress on Thrombosis – The Start of a New Era – Antithrombotic Agents, Milan, Italy, 6–9 July 2010 | B |
| Verso M, Agnelli G, Ageno W, Imberti D, Moia M, Palareti G, et al. Long-term clinical outcomes in patients with venous thromboembolism: findings From the master registry. 21st International Congress on Thrombosis – The Start of a New Era – Antithrombotic Agents, Milan, Italy, 6–9 July 2010 | B |
| Cosmi B, Legnani C, Iorio A, Pengo V, Ghirarduzzi A, Testa S, et al. Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep-vein thrombosis in the prolong study. Eur J Vasc Endovasc Surg 2010;39:356–65 | B |
| Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, et al. Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. J Thromb Haemost 2010;8:1933–42 | B |
| Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, et al. Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study. Thromb Haemost 2010;103:1152–60 | B |
| Lewis DA, Stashenko GJ, Akay OM, Price LI, Owzar K, Ginsburg GS, et al. Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism. Thromb Res 2011;128:536–40 | B |
| Heit JA, Lahr BD, Petterson TM, Bailey KR, Ashrani AA, Melton LJ III. Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep-vein thrombosis or pulmonary embolism: a population-based cohort study. Blood 2011;118:4992–9 | B |
| Andresen MS, Sandven I, Brunborg C, Njaastad AM, Strekerud F, Abdelnoor M, et al. Mortality and recurrence after treatment of VTE: long term follow-up of patients with good life-expectancy. Thromb Res 2011;127:540–6 | B |
| Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ 2011;342:d3036 | B |
| Douketis J, Tosetto A, Marcucci M, Baglin T, Cosmi B, Cushman M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 2011;342:d813 | B |
| Ortel TL, Beckman M, Hooper WC, Lewis DA, Chi J-T, Kenney KM, et al. Identification of patients at high risk for recurrent venous thromboembolism by whole blood gene expression analysis. 53rd Annual Meeting of the American Society of Haematology 2011, San Diego, CA, 10–13 November 2011 | B |
| Gauthier K, Sabri E, Kahn SR, Wells PS, Anderson D, Gal GL, et al. Family history of venous thromboembolism (VTE) and the risk of VTE recurrence in patients with a first unprovoked VTE: a multicenter prospective cohort study. 53rd Annual Meeting of the American Society of Haematology 2011, San Diego, CA, 10–13 November 2011 | B |
| Papadakis E, Theocharidou D, Mpanti A, Spyrou A, Loukidis K, Tsepanis K, et al. Anatomical distribution of first VTE event and risk of VTE recurrence: long term follow-up and retrospective analysis of 346 Patients. Experience from a single centre. 53rd Annual Meeting of the American Society of Haematology 2011, San Diego, CA, 10–13 November 2011 | B |
| Spirk D, Aujesky D, Husmann M, Hayoz D, Baldi T, Frauchiger B, et al. Cardiac troponin testing and the simplified pulmonary embolism severity index. The Swiss venous thromboembolism registry (SWIVTER). Thromb Haemost 2011;106:978–84 | B |
| Douketis J. D-dimer can predict risk of recurrent venous thromboembolism regardless of patient age, timing of testing, or characteristics of assay. J Clin Outcomes Manag 2011;18:246–8 | B |
| Wang Y, Liu Z. Elevated N-terminal pro-brain natriuretic peptide increases the risk of recurrent thromboembolic events after acute pulmonary embolism. American Heart Association’s Scientific Sessions 2011, Orlando, FL, 12–16 November 2011 | B |
| Vorob’eva NM, Khasanova ZB, Doroshchuk NA, Postnov AY, Kirienko AI, Panchenko EP. Fibrinogen-Beta-249C/T polymorphism is a novel genetic predictor for recurrence of deep-vein thrombosis in Russian population. 23rd Congress of the International Society on Thrombosis and Haemostasis, 57th Annual SSC Meeting, Kyoto, Japan, 23–28 July 2011 | B |
| Traby L, Heinze G, Kollars M, Eischer L, Eichinger S, Kyrle PA. Hypofibrinolysis and the risk of recurrent venous thromboembolism: a prospective cohort study. 23rd Congress of the International Society on Thrombosis and Haemostasis, 57th Annual SSC Meeting, Kyoto, Japan, 23–28 July 2011 | B |
| Ten Cate-Hoek AJ, Erkens P, Hamulyak K, Verhezen P, Ten CH. Is the predictive quality of D-dimer for the recurrence of thrombosis time dependent? 23rd Congress of the International Society on Thrombosis and Haemostasis 57th Annual SSC Meeting, Kyoto, Japan, 23–28 July 2011 | B |
| Spirk D, Ugi J, Korte W, Husmann M, Hayoz D, Baldi T, et al. Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer: The Swiss venous thromboembolism registry (SWIVTER) II. Thromb Haemost 2011;105:962–7 | B |
| Gandara E, Kovacs MJ, Kahn S, Wells P, Anderson DA, Solymoss S, et al. Does ABO blood group increase the rate of recurrent events after initial treatment for a first unprovoked venous thromboembolism (VTE) Event? Reverse cohort subgroup analysis. 23rd Congress of the International Society on Thrombosis and Haemostasis 57th Annual SSC Meeting, Kyoto, Japan, 23–28 July 2011 | B |
| Ruiz-Artacho P, Pedrajas-Navas JM, Molino-Gonzalez A, Sendin-Martin V, Sanchez-Martinez N, Gonzalez-Casanova B. et al. Idiopathic venous thromboembolism: risk factors of recurrence and optimal duration of anticoagulant therapy. 10th Congress of the European Federation of Internal Medicine, Athens, Greece, 5–8 November 2011 | B |
| Yuan Y-D, Gong X-W, Yang Y-H. [Meta-analysis of risk factors for recurrent pulmonary thromboembolism.] Nat Med J Chin 2012;92:2419–25 | B |
| Verso M, Agnelli G, Ageno W, Imberti D, Moia M, Palareti G, et al. Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry. Thromb Res 2012;130:369–73 | B |
| Galanaud JP, Bosson JL, Genty C, Presles E, Cucherat M, Sevestre MA, et al. Superficial vein thrombosis and recurrent venous thromboembolism: a pooled analysis of two observational studies. J Thromb Haemost 2012;10:1004–11 | B |
| Wang Y, Liu Z-H, Zhang H-L, Luo Q, Zhao Z-H, Zhao Q. Association of elevated NTproBNP with recurrent thromboembolic events after acute pulmonary embolism. Thromb Res 2012;129:688–92 | B |
| Lutsey PL, Folsom AR. Taller women are at greater risk of recurrent venous thromboembolism: the Iowa Women’s Health Study. Am J Hematol 2012;87:716–17 | B |
| van Schouwenburg IM, Mahmoodi BK, Veeger NJ, Kluin-Nelemans HC, Gansevoort RT, Meijer K. Elevated albuminuria associated with increased risk of recurrent venous thromboembolism: results of a population-based cohort study. Br J Haematol 2012;156:667–71 | B |
| Poli D, Cenci C, Antonucci E, Grifoni E, Arcangeli C, Prisco D, et al. Risk of recurrence in patients with pulmonary embolism: predictive role of D-dimer and of residual oerfusion defects on lung scintigraphy. 22nd National Congress of the Italian Society for Thrombosis and Hemostasis – SISET Vicenza, Italy, 4–6 October 2012 | B |
| Cosmi B, Legnani C, Ghiraduzzi A, Testa S, Vittorio P, Favaretto E, et al. D-Dimer and ultrasound in combination Italian study (Dulcis) to establish the optimal duration of anticoagulation for venous thromboembolism: preliminary results. 58th Annual Meeting of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis, Liverpool, 27–30 June 2012 | B |
| Donadini MP, Ageno W, Antonucci E, Cosmi B, Kovacs MJ, Le GG, et al. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep-vein thrombosis: a patient-level meta-analysis. Thromb Haemost 2014;111:172–9 | B |
| Donovan AK, Smith KJ, Ragni MV. Anticoagulation duration in heterozygous factor V Leiden: a decision analysis. Thromb Res 2013;132:724–8 | B |
| Lijfering W, Braekkan S, Caram-Deelder C, Rosendaal FR, Cannegieter SC. Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study. 55th Annual Meeting of the American Society of Haematology 2013, New Orleans, LA, 7–10 December 2013 | B |
| Martinez C, Katholing A, Cohen A. Risk factors for recurrent venous thromboembolism: VTE Epidemiology Group (VEG) Study. 24th Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, Netherlands, 29 June–4 July 2013 | B |
| Memon AA, Sundquist J, Zoller B, Wang X, Dahlback B, Svensson PJ, et al. Apolipoprotein M and the risk of unprovoked recurrent venous thromboembolism. Thromb Res 2014;133:322–6 | B |
| van Hylckama Vlieg A, Flinterman LE, Bare LAL, Cannegieter SC, Arellano AR, Tong CH, et al. Assessment of the risk of recurrent venous thrombosis using a genetic risk score comprising five genetic markers. 24th Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, 29 June–4 July 2013 | B |
| Wicki J, Perrier A, Perneger TV, Bounameaux H, Junod AF. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 2000;84:548–52 | C |
| Baloira VA, Ruiz Iturriaga LA. [Pulmonary thromboembolism.] Arch Bronconeumol 2010;46:31–7 | C |
| Kooiman J, Van HN, Iglesias Del SA, Planken E, Lip GYH, Van Der Meer FJM, et al. Predictive Value of the HAS-BLED score for major bleeding in patients with venous thromboembolism during anticoagulant treatment. 24th Congress of the International Society on Thrombosis and Haemostasis Amsterdam, Netherlands, 29 June–4 July 2013 | C |
| Schulman S. How long should oral anticoagulation continue after venous thromboembolism? Cardiology Rev 1996;13:13–16 | B, C |
| Sarasin FP, Bounameaux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep-vein thrombosis. BMJ 1998;316:95–9 | B, C |
| Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep-vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769–74 | B, C |
| Vink R, Kraaijenhagen RA, Levi M, Buller HR. Individualised duration of oral anticoagulant therapy for deep-vein thrombosis based on a decision model. J Thromb Haemost 2003;1:2523–30 | B, C |
| Breddin HK, Kadziola Z, Scully M, Nakov R, Misselwitz F, Kakkar VV. Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep-vein thrombosis. Thromb Haemost 2003;89:272–7 | B, C |
| Rose P, McManus A, Paneesha S, Scriven N, Farren T, Bacon S, et al. Clinical predictors of adverse outcome in VTE outpatients – the VERITY PUSH Study. 50th Annual Scientific Meeting of the British Society for Haematology, Edinburgh, 19–21 April 2010 | B, C |
| Roh BS, Bang D-H, Lee YH. Recurrent venous thrombosis after endovascular management of iliofemoral deep-vein thrombosis: incidence and risk factors. Cardiovascular and Interventional Radiological Society of Europe, CIRSE 2010, Valencia, Spain, 2–6 January 2010 | B, C |
| Rose P, McManus A, Paneesha S, Scriven N, Farren T, Bacon S, et al. Clinical predictors of adverse outcome in VTE outpatients – analysis of patients with ‘first event’ VTE. 21st International Congress on Thrombosis – The Start of a New Era – Antithrombotic Agents Milan, Italy, 6–9 July 2010 | B, C |
| Chen S, Gulseth MP, Bookhart B, Boulanger L, Fields LE, Schein J, et al. Compliance with warfarin treatment for venous thromboembolism in high-risk patients and its association with recurrent events. Conference: 24th Annual Meeting and Expo of the Academy of Managed Care Pharmacy, AMCP 2012 San Francisco, CA, 18–20 March 2012 | B, C |
| Alhadad A, Miniati M, Alhadad H, Gottsater A, Bajc M. The value of tomographic ventilation/perfusion scintigraphy (V/PSPECT) for follow-up and prediction of recurrence in pulmonary embolism. Thromb Res 2012;130:877–81 | B, C |
| Cohen AT, Rietbrock S, Martinez C. Mortality Following venous thromboembolism. Risk factors from a large cohort. VTE Epidemiology Group (VEG) Study. 24th Congress of the International Society on Thrombosis and Haemostasis Amsterdam, Netherlands, 29 June–4 July 2013 | B, C |
| Poli D, Cenci C, Antonucci E, Grifoni E, Arcangeli C, Prisco D, et al. Risk of recurrence in patients with pulmonary embolism: predictive role of D-dimer and of residual perfusion defects on lung scintigraphy. Thromb Haemost 2013;109:181–6 | B, C |
| Wang Y, Zhang XT. [Analysis of the risk factors influencing the recurrence of deep venous thrombosis in lower extremity after interventional treatment.] J Interv Radiol (China) 2013;22:764–7 | B, C |
| Wiggins KL, Harrington LB, Blondon M, Rice KM, Sitlani CM, Heckbert SR, et al. Risk factors for incident venous thrombosis and their associations with recurrence. American Heart Association’s Epidemiology and Prevention/Nutrition, Physical Activity, and Metabolism 2014 Scientific Sessions, San Francisco, CA, 18–21 March 2014 | B, C |
